COVID-19 diagnosis by routine blood tests using machine learning by Kukar, Matjaž et al.
1COVID-19 diagnosis by routine blood tests  
using machine learning
Matjaž Kukar,1,2* Gregor Gunčar,1,3* Tomaž Vovko,4 Simon Podnar,5 Peter Černelč,7 Miran Brvar,6 
Mateja Zalaznik,4 Mateja Notar,1 Sašo Moškon,1 Marko Notar#1
1Smart Blood Analytics Swiss SA, CH-8008 Zürich, Switzerland
2Faculty of Computer and Information Science, University of Ljubljana, Slovenia
3Faculty of Chemistry and Chemical Technology, University of Ljubljana, Slovenia
4Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia
5Division of Neurology, University Medical Centre Ljubljana, Slovenia
6Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Slovenia
7Division of Internal Medicine, University Medical Centre Ljubljana, Slovenia
*Joint first authors, contributed equally. 
#Corresponding author marko@sba-swiss.com
Abstract
Physicians taking care of patients with coronavirus disease (COVID-19) have described different 
changes in routine blood parameters. However, these changes, hinder them from performing 
COVID-19 diagnosis. We constructed a machine learning predictive model for COVID-19 diag-
nosis. The model was based and cross-validated on the routine blood tests of 5,333 patients 
with various bacterial and viral infections, and 160 COVID-19-positive patients. We selected op-
erational ROC point at a sensitivity of 81.9% and specificity of 97.9%. The cross-validated area 
under the curve (AUC) was 0.97. The five most useful routine blood parameters for COVID19 
diagnosis according to the feature importance scoring of the XGBoost algorithm were MCHC, 
eosinophil count, albumin, INR, and prothrombin activity percentage. tSNE visualization 
showed that the blood parameters of the patients with severe COVID-19 course are more like 
the parameters of bacterial than viral infection. The reported diagnostic accuracy is at least 
comparable and probably complementary to RT-PCR and chest CT studies. Patients with fever, 
cough, myalgia, and other symptoms can now have initial routine blood tests assessed by our 
diagnostic tool. All patients with a positive COVID-19 prediction would then undergo standard 
RT-PCR studies to confirm the diagnosis. We believe that our results present a significant con-
tribution to improvements in COVID-19 diagnosis.
Keywords: COVID-19, artificial intelligence, machine learning, blood test, diagnostic accuracy, 
respiratory infection, SARS-CoV-2
Introduction
In December 2019, cases of pneumonia of an unknown origin were identified in Wuhan, the 
capital of Hubei province, China [1]. The causative agent was named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2)[2], and the disease was named coronavirus disease (CO-
VID-19). Soon after, it was realized that SARS-CoV-2 is a highly contagious and moderately viru-
lent virus[3]. In the following months, SARS-CoV-2 spread worldwide, and on March 11, 2020, 
the World Health Organization (WHO) declared COVID-19 a pandemic [4]. Although clinical 
features of COVID-19 patients were soon described [5,6], no vaccination or effective treatment 
was available. Currently, the only effective measures for stopping COVID-19 spread are strict 
precautionary hygiene, social distancing, and isolation of contagious subjects [7,8]. 
2COVID-19 diagnosis is crucial for the identification, isolation, and treatment of contagious sub-
jects [9]. The gold standard for COVID-19 diagnosis is a demonstration of SARS-CoV-2 RNA in 
patients’ respiratory secretions using real-time reverse transcriptase polymerase chain reac-
tion (RT-PCR) [10,11]. Although RT-PCR is invaluable in dealing with the COVID-19 pandemic, it 
is a sophisticated test that requires extensive and delicate infrastructure [10]. Moreover, the 
test is not always positive even in fully symptomatic SARS-CoV-2 infected patients [12]. Some 
authors have reported only 30%-60% sensitivity of RT-PCR in clinical applications [13,14]. Ad-
ditionally, demand for RT-PCR testing is enormous, which is a limitation in the control of the 
pandemic [15]. In symptomatic COVID-19 patients, a CT scan of the chest is a useful [13] but 
undesirable alternative [16]. Therefore, other testing methods are imperative. 
Physicians taking care of COVID-19 patients have noted pronounced changes in their blood 
parameters. Particularly, they have described hypoalbuminemia, increased C-reactive protein 
(CRP) and lactate dehydrogenase (LDH), lymphopenia, etc. [17]. Nevertheless, these labora-
tory findings alone are insufficient for physicians to differentiate patients with COVID-19 from 
patients with other infectious disorders. More so, it is widely known that even the most knowl-
edgeable and experienced physicians can extract only a minor fraction of information con-
tained in the results of routine blood tests [18]. By contrast, machine learning (ML) can rec-
ognize subtle patterns in data. Therefore, ML is suitable for differentiating various patterns 
observed in routine blood parameters. We have previously demonstrated how an ML model 
considerably outperformed experienced clinicians in diagnosing hematological disorder [18], 
as well as another model (similar to head imaging) with diagnostic accuracy for brain tumors 
[19].
The aim of the present study is to determine the diagnostic accuracy of a ML model built spe-
cifically for the diagnosis of COVID-19 using results of routine blood tests. A group of symptom-
atic patients newly diagnosed with COVID-19 and patients with other infectious diseases were 
studied. 
Materials and methods
Patients and controls
A pool of a COVID-19-positive population was obtained in March/April 2020 from patients 
admitted to the Department of Infectious Diseases, University Medical Centre Ljubljana 
(UMCL), Slovenia. The training positive group included 160 consecutive symptomatic pa-
tients. 
A pool of a COVID-19-negative population was obtained from 52,306 patients admitted to 
the same Department from March, 2012 to April, 2019. A more representative population 
of 22,385 patients with various viral and bacterial infections, and approximately the same 
mean number of measured blood parameters as in the COVID-19-positive patients (33 out 
of 35) was selected. To construct the final representative training negative group, patients 
were randomly sampled (without replacement) to approximate the proportion of positive 
versus tested individuals (3% at the time of data collection). At the end, the training nega-
tive group included retrospective data of 5,333 patients with 225 different bacterial and 
viral infections (different ICD codes), diagnosed prior to the COVID-19 outbreak (Fig 1). 
3Fig 1. A flow chart of patients included in the model building and validation process.
In all groups, we collected data on patients’ age, sex, routine blood test results, and the 
ICD10-encoded final diagnoses. All identifiable personal data items were removed prior to 
analysis. The National Ethics Committee of Slovenia approved the study (No. 0120-718/2015/7, 
No. 0120-170/2020/6). Due to the retrospective design, the necessity of obtaining patients’ 
written informed consent was waived. The study was performed in accordance with the STARD 
recommendations [20].
Blood parameters used for model building
Out of 117 parameters measured in the training positive group, we removed all param-
eters that were measured in less than 25% of the patients. We also omitted non-blood 
parameters and arterial blood parameters. Thus, 35 parameters were selected. For each 
parameter, we calculated the relative reference range and median values for a group of pa-
tients with COVID-19, and in the training negative group, we calculated for the viral and bacte-
rial infections separately. All parameter values (reference ranges, medians) were centered and 
scaled according to reference ranges. We compared blood parameter distributions in groups 
by the nonparametric k-sample Anderson-Darling (AD) test and depicted the P-values [21].
Visualization of blood parameter space
To visualize how the data was arranged in a high-dimensional space of 35 blood parameters, 
we applied the t-distributed stochastic neighbor embedding (t-SNE) method [22], which is an 
unsupervised, non-linear technique primarily used for data exploration and visualization of 
high-dimensional data. The method has been shown to perform effectively in several high-
dimensional datasets, it is very flexible, and it can often find a structure where other dimen-
sionality-reduction algorithms fail [22,23]. The nature and complexity of t-SNE may lead to 
visualization misinterpretation, specifically to overstating the meaning of distances on the plot 
[24]. In this work, we used the openTSNE implementation [25,26].
4Smart Blood Analytics machine learning algorithm
The Smart Blood Analytics (SBA) algorithm is a CRISP-DM based machine learning pipeline con-
sisting of five processing stages corresponding to phases 2-6 of the CRISP-DM [27] standard. 
The stages are as follows. Data acquisition: acquiring raw data from the database; data filter-
ing: constructing the training dataset consisting of blood test results obtained before treat-
ment and the patient’s final diagnosis; data preprocessing: canonization of blood parameters 
(matching them with our reference blood parameter database, recalculation to SI units, data 
quality control); data modelling: building the diagnostic model using ML algorithms; evaluation: 
evaluating the model with stratified ten-fold cross-validation and/or independent testing data; 
deployment of the successfully evaluated model in the cloud (accessible either through hos-
pital information systems or the SBA website[28]). As the principal ML algorithm, we utilized 
either random forests (RF), deep neural networks (DNN), or the extreme gradient boosting 
machine (XGBoost). To diagnose the COVID-19 disease, the XGBoost [29-31] learning algorithm 
was chosen after initial experimental runs of all three candidates as it produced models with 
significantly higher performances and required less computational resources. Incidentally, XG-
Boost is currently one of the most popular ML tools [32] with key strengths, such as speed and 
parallelization; more importantly, it can intrinsically handle sparse (missing) data, which many 
other algorithms struggle with [33].
Imbalanced data and model calibration
In our data, we observed severely imbalanced groups (in daily practice, the ratio of positive 
versus tested is approximately 3%). However, such a scenario is often problematic for machine 
learning algorithms as it makes it too easy to focus on the prevalent group (negatives). Sim-
ple data undersampling techniques failed to improve the results due to the relatively large 
number of blood parameters and a correspondingly large (35+2)-dimensional attribute space. 
Moreover, more advanced resampling techniques, such as SMOTE [34,35], struggle with high-
dimensional and interdependent data [36], such as blood test measurements. Therefore, un-
dersampling was only used to maintain the ratio between the positive and negative groups. 
Additionally, the intrinsic imbalance was addressed by model calibration using the precision-
recall (PR) curve [37] and maximizing the F2-score (favoring recall versus precision) to select the 
operational ROC point.
Evaluation of predictive models
The models were evaluated in two different ways. First, we automatically evaluated the models 
using repeated stratified ten-fold cross-validation. The results were characterized using stan-
dard performance measures, such as sensitivity and specificity (recall on positive and negative 
groups, respectively), precision, AUC, and ROC curve. Additionally, we tested the final model on 
a separate control group and reported the same performance measures. Furthermore, for sen-
sitivity and specificity, the 95% binominal confidence intervals using the Agresti-Coull method 
were calculated [38].
Results
Demographic data for all patient groups are presented in table 1. Out of the 160 COVID-
19-positive patients (median age: 55.5 years; 42% women), 17 were admitted to the inten-
sive care unit (ICU), and 14 required intubation and invasive mechanical ventilation. Chest 
X-ray was performed on 94 patients, and lung infiltrates were detected in 68 patients. Respira-
5tory failure occurred in 44 patients (27.5%), 10 died (6%), 7 were still in the ICU (4%), and 20 
were in the hospital (12.5%). The following comorbidities were also present: hypertension in 
34.4%, diabetes in 9.4%, hyperlipidemia in 11.9%, heart failure in 7.5%, hypothyroidismin in 
6.3%, atrial fibrillation in 5.0%, ischemic heart disease in 3.8%, COPD or asthma in 5.6%, chronic 
kidney failure in 3.8%, and occlusive peripheral arterial disease in 1.9%. 
Table 1. Demographic features of included patient groups.
Training group – COVID-19
Negative Positive
Number 5333 160
Age median 57 55.5
Female number/% 2155/40% 67/42%
Fig 2. Blood parameters sorted by their XGBoost importance score (more important parameters are shown on the left). Group median 
values and IQR of the blood parameters used in model building are shown, centered, and scaled to reference intervals. Median bar for 
the C-reactive protein in bacterial infections is out of the scale at 38 mg/L. Groups (COVID-19/other virus/bacteria) were evaluated by the 
Anderson-Darling test. The significance levels (0.05 or 0.01) of the test results are depicted at the bottom.
The analysis of 35 selected blood parameters revealed that in the COVID-19 positive group, 
the calculated parameter medians were within the normal reference range for all except 
two parameters that were elevated: prothrombin activity % (median: 1.05; normal range 
(SI): 0.7-1), and CRP (median: 12 mg/L; SI: 0-5 mg/L) (Fig 2). Most blood test parameters 
6from the patients with COVID-19 differed significantly from patients with other viral and 
bacterial infections. Five parameters with the statistically most significant difference and 
effect size between the COVID-19-positive group and bacterial infections were urea, he-
moglobin, erythrocyte count, hematocrit, and leukocyte count. When the COVID-19-posi-
tive group was compared to other viral infections, the five parameters with the statistically 
most significant difference and effect size were mean corpuscular hemoglobin concen-
tration (MCHC), eosinophils ratio, prothrombin international normalized ratio (INR), pro-
thrombin activity %, and creatinine (Fig 2). According to the XGBoost feature importance 
scoring, the five blood parameters with the highest discriminative power were MCHC, 
eosinophils count, albumin, INR and prothrombin activity %. 
The full complexity of COVID-19 diagnostics can be illustrated by visualizing the blood param-
eter space of patients with COVID-19, bacterial, and viral infection from our training data us-
ing the t-SNE method [22] (Fig 3). Even after extensive experimentation, which also included 
alternative visualization techniques, such as PCA and MDS, it was impossible to obtain partial 
separation of the positive and negative groups. While the virus and bacteria subgroups appear 
different, but have a significant overlap, the COVID-19 positive group is dispersed between 
both. Expectedly, the medoid of the COVID-19 positive group lies closer to the medoid of the vi-
rus subgroup than to the medoid of the bacteria subgroup. This is not the case in the COVID-19 
positive patients who died or had a diagnosis of acute respiratory failure (ARF). The medoids of 
those patients are both closer to the medoid of the bacteria subgroup (Fig 3). 
Fig 3. Visualization of bacteria/virus/COVID-19 parameter space with t-SNE method. Medoids of bacteria/virus/COVID-19 groups are 
marked. Each dot represents a patient (more specifically, an embedding of his/her blood parameters into a two-dimensional space), and 
its color represents the group. Green dots represent patients who died (A) and patients diagnosed with acute respiratory failure (B).
Nevertheless, the predictive model for the diagnosis of COVID-19, which was produced us-
ing XGBoost, performed effectively (Fig 2). In the training group, using ten-fold stratified cross-
validation testing procedure, the results and the corresponding binomial confidence intervals, 
calibrated with respect to the operational ROC point were as follows: a sensitivity of 81.9% ± 6, 
specificity of 97.9% ± 0.4%, and AUC of 0.97 (table 2, Fig 4).
7Table 2. Confusion table for the cross-validated training group
Positive Negative
Predicted positive 131 112
Predicted negative 29 5221
Discussion
In this study, we confirmed that COVID-19 diagnosis is attainable using ML on data from rou-
tine blood tests. We demonstrated that our ML model efficiently discriminated patients with 
COVID-19 from patients with other infectious diseases. The model exhibited a high sensitivity 
of 81.9%, a specificity of 97.9%, and an AUC of 0.97 on the cross-validated training group (Fig 
4). From an ML perspective, our results are quantitatively excellent, with an impressively low 
proportion of false positives and a moderately low proportion of false negatives. Moreover, 
AUC values above 0.90 are generally considered as excellent [39].
Owing to the absence of a completely reliable diagnostic standard for COVID-19, it is difficult 
to evaluate the diagnostic performance of various diagnostic tests. Nevertheless, it is clear 
that the diagnostic performances of both RT-PCR studies and chest CT are not perfect. In a 
recent study of 1,014 patients suspected with COVID-19, both tests were positive in 580 cases, 
only chest CT was positive in 308, only RT-PCR in 21, and none of them in the remaining 105 
Fig 4. ROC, PR (precision-recall), and F2 curves for COVID-19 diagnosis calculated from the training data using ten-fold stratified cross-
validation. Vertical and horizontal dashed lines connect the F2 (gray) max point with the PR curve (orange) and the ROC curve (blue) in 
order to obtain the operational ROC point with sensitivity = 0.819, specificity = 0.979 (depicted with red dots), and AUC = 0.97. 
8patients; RT-PCR sensitivity was 59%, and chest CT was 88% [13]. The diagnostic performance 
of our predictive model is most likely not inferior to its competitors. Furthermore, it is most 
probably complementary and would be best used along with standard protocols designed ac-
cording to local circumstances.
In a study describing a ML model using blood parameters [40], the researchers studied 105 pa-
tients with COVID-19 and 148 patients with other pulmonary disorders. They identified 11 most 
useful blood parameters (total protein, bilirubin, glucose, creatinine, Ca, LDH, creatine kinase, 
K, Mg, platelet distribution width, and basophil count) and used them in their analyses. They 
also recorded high test accuracies: 98% on cross-validation and 97% on test set [40]. Although 
their work has not been peer-reviewed and published in a scientific literature, their data con-
firm our finding that ML models using routine blood parameters is useful in the diagnosis of 
COVID-19. However, their data quantitatively has a 41% ratio of positives. Thus, where the ratio 
is much lower in practice, unacceptably high numbers of false positives would be recorded.
In another study, the authors collected 102 patients diagnosed as positive and 133 diagnosed 
as negative with RT-PCR tests.[41] Their best results are considerably lower than ours (AUC: 
0.85, sensitivity 0.68, specificity 0.85), most likely due to a much lower number of blood pa-
rameters measured (only 13). As demonstrated in the study [40], it is difficult to assess the 
practical importance of their results as the 43% ratio of positives would in practice be much 
smaller and again result in high numbers of false positives. 
We obtained blood samples from our patients immediately after they were presented to the 
infectious disease service. This observation suggests that the SBA algorithm is useful in the 
early symptomatic phase when COVID-19 is easier to be missed by RT-PCR test. We do not 
have data on the ability of our model to diagnose presymptomatic COVID-19 patients as their 
blood had not been drawn. Although this should be tested in the future, our model will pos-
sibly be inefficient at that stage in which the virus replicates locally in the nasopharynx without 
systemic effects. 
Some routine blood parameters proved to be especially important in our model. It should be 
noted that we selected the blood parameters we used for model training and analysis based on 
the available data in all of our patient groups. Therefore, we were unable to include some clini-
cally relevant parameters that might be helpful in identifying patients with COVID-19. However, 
our analysis revealed some blood parameters that require further investigation in patients 
with COVID-19. In our analysis, the two out of five most discriminating parameters for patients 
with COVID-19 were prothrombin activity % and INR, which were elevated and decreased, 
respectively, indicating accelerated blood clot formation in patients with COVID-19. The risk 
of disseminated intravascular coagulation and venous thromboembolism is well recognized in 
COVID-19 [42]. We also observed raised MCHC, a reduction in eosinophils, low albumin levels, 
high CRP, and lymphopenia (Fig 2). In a systematic review and meta-analysis of 19 studies, the 
most prevalent laboratory abnormalities found in patients with COVID-19 were hypoalbumin-
emia (76%), increased CRP (58%), LDH (57%), and lymphopenia (43%) [17]. However, this pat-
tern of abnormalities is still rather nonspecific and does not enable physicians to diagnose CO-
VID-19. Likewise, considering the 35 most important parameters we analyzed (Fig 2) does not 
enable physicians to confirm COVID-19 diagnosis. This is also evident from our t-SNE analysis 
and visualization of the distribution of COVID-19, bacterial infection, and viral infection cases, 
which showed the complexity of the parameter space in COVID-19 (Fig 3). Apart from diagno-
sis, physicians caring for patients with COVID-19 also noted some typical patterns in blood pa-
9rameters that predict more severe disease courses. Most notably in patients with more severe 
disease courses, laboratory abnormalities were more pronounced (e.g., more severe lympho-
penia, CRP and LDH increase, etc.) [5]. In agreement, our t-SNE visualization of blood parameter 
space shows that the medoid of the patients with severe COVID-19 course is shifted toward the 
medoid of the patients with bacterial infection (Fig 3). This indicates for the need of COVID-19 
patients to be tested for bacteria or severe inflammation early on and treated accordingly.  It 
also shows the possibility of the efficient prognostication of the COVID-19 course using ML. 
Our study has several limitations. First, our analysis was performed on data obtained in a single 
center. Although this may limit generalizability, using standardized and approved procedures, 
reagents, and technology, we expect similar laboratory blood test results in other centers. Sec-
ond, the number of COVID-19-positive patients included in our analyses was limited (160 for 
the building of the ML model). Both data disproportion and parameter dimensionality suggest 
that a considerably higher number of positive patients (at least 1,000) would further improve 
results on the positive group. However, with respect to the small number of available COVID-
19-positive patients, the current results are excellent. Third, the study was retrospective, which 
limited the scope of available patient data. However, for the purpose of this study, we mainly 
required available results of routine blood tests and accurate COVID-19 diagnoses. 
The study also has several strengths. First, we analyzed data from a large number of patients 
(> 5,000) with good data quality for blood tests and diagnoses. Second, a single certified labo-
ratory diagnosed all patients with COVID-19 using RT-PCR, which assured the high quality of 
the diagnoses. The specificity of RT-PCR was also very high. Furthermore, high specificity was 
assured by the inclusion of patients evaluated for various infectious diseases before the CO-
VID-19 pandemic. Third, we used state-of-the-art ML algorithms that can develop the best 
predictive models. 
The study demonstrates that symptomatic patients with COVID-19 can be efficiently diag-
nosed from the results of routine blood tests.  The SBA COVID-19 ML model extracted subtle 
prognostic data from blood test results that were hidden from the most experienced clini-
cians. We believe that our results present an important step to a more widely available diag-
nosis of patients with COVID-19. Moreover, our ML predictive model is available worldwide at 
www.smartbloodanalytics.com as a web application or through an API call, and it can be used 
instantly. The model will also be of benefit after the pandemic as it will be an alternative for a 
physician to test patients for COVID-19 from the blood test results of other diagnoses. 
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